A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma

Affiliations

¹ Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
² First Department of Medicine - Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.
³ Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
⁴ Department of Mathematical Analysis and Application of Mathematics, Faculty of Science, Palacky University, Olomouc, Czech Republic.
⁵ Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
⁶ Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Prague, Czech Republic.

Ales Obr et al. Br J Haematol. 2020 Dec.

. 2020 Dec;191(5):e103-e106.

doi: 10.1111/bjh.17063. Epub 2020 Aug 30.

¹ Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
² First Department of Medicine - Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.
³ Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
⁴ Department of Mathematical Analysis and Application of Mathematics, Faculty of Science, Palacky University, Olomouc, Czech Republic.
⁵ Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
⁶ Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Prague, Czech Republic.

No abstract available

Keywords: TP53 aberration; chemoresistance; mantle cell lymphoma; mutation burden.

References

1. Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, van Hoof A, et al. Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the European mantle-cell lymphoma network. J Clin Oncol. 2014;32:1338-46.
1. Klener P. Advances in molecular biology and targeted therapy of mantle cell lymphoma. Int J Mol Sci. 2019;20:4417.
1. Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903-10.
1. Delfau-Larue M-H, Klapper W, Berger F, Jardin F, Briere J, Salles G, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126:604-11.
1. Obr A, Procházka V, Jirkuvová A, Urbánková H, Kriegova E, Schneiderová P, et al. TP53 mutation and complex karyotype portends a dismal prognosis in patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18:762-8.